MXCT Earnings

MXCT reported its earnings on 2026-03-24, showcasing a revenue of 7.30M against an estimate of 9.20M, resulting in a -20.65% surprise. The EPS was -0.06, surpassing the expected -0.08 by 25%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MXCT's earnings announcement on 2026-03-24, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, MXCT's stock price tends to shift by an average of 3.47% in the 10 days leading up to earnings and 0.5% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MXCT's annual revenue to reach 8.84M, while the EPS is projected at -0.06. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MXCT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MXCT's stock price typically moves by 3.47% in the 10 days before its earnings and 0.5% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.06 and revenue of 8.84M.

The company's strong revenue growth, improved gross margin, and reduced net loss indicate positive financial performance. The optimistic revenue expectations and margin projections for 2026 further enhance the outlook. Although operational updates and risks were not discussed, the focus on product expansion and market recovery in biotech are promising. The absence of shareholder return details is a minor concern. Overall, the positive financial metrics and strategic initiatives suggest a likely positive stock price movement in the near term.